错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

IPNA consensus definitions for clinical trial outcomes in steroid-resistant nephrotic syndrome

  • Pankaj Hari,
  • Priyanka Khandelwal,
  • Olivia Boyer,
  • Rajendra Bhimma,
  • Francesco Cano,
  • Martin Christian,
  • Ali Duzova,
  • Kazumoto Iijima,
  • Hee Gyung Kang,
  • Shen Qian,
  • Hesham Safouh,
  • Susan Samuels,
  • William E. Smoyer,
  • Marina Vivarelli,
  • Arvind Bagga,
  • Franz Schaefer

摘要

Assessment of the true impact of therapeutic interventions is a challenge in the absence of universal, standardized definitions for clinical trial endpoints in children with kidney diseases. Steroid-resistant nephrotic syndrome (SRNS) is a difficult kidney disease to treat, with unremitting disease progressing to kidney failure. Currently, available therapies result in suboptimal cure rates. Clinical trials with innovative, targeted treatments will likely be conducted for this disease in the foreseeable future. An international consortium of the IPNA Best Practices and Standards Committee and the Pediatric Nephrology Expert Group of the conect4children (c4c) network developed through consensus, standardized, internationally acceptable definitions for trial outcomes for SRNS. The endpoint definitions were formulated for use with urine protein to creatinine ratios and estimated glomerular filtration rates. Definitions of complete remission, partial remission, non-remission of disease, reduction in proteinuria, kidney disease progression, kidney failure, and composite kidney outcome were refined using an iterative process until a consensus was achieved.